Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/28/2026

1. NVDA
2. SPY
3. MPLT
4. USO
5. BSP
6. CAPR
7. XFLT
8. HCA
9. MSFT
10. META

Go back to Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program
Merck & Co. (NYSE: MRK) Delayed: 130.76 --0 (-0%)
Previous Close $130.76    52 Week High $65.46 
Open $130.76    52 Week Low $47.97 
Day High $130.76    P/E 88.95 
Day Low $130.76    EPS $1.47 
Volume 2,622